Core Viewpoint - The company announced that its wholly-owned subsidiary, Qichao Biotechnology, has completed the construction of a biopesticide raw material and formulation relocation project, which is now ready for trial operation [1] Group 1: Project Details - The project focuses on the research and production of gibberellin series raw materials and formulations, as well as new environmentally friendly pesticide formulation products [1] - Upon reaching full production capacity, the project is expected to achieve an annual output of 3,261 tons of raw material formulations and 20 million tablets [1]

Core Viewpoint - Qianjiang Biochemical (600796) announced that its wholly-owned subsidiary, Qichao Biotechnology, has completed the construction of a biopesticide raw material and formulation relocation project, which is now ready for trial operation [1] Group 1: Project Details - The project focuses on the research and production of gibberellin series raw materials and formulations, as well as new environmentally friendly pesticide formulations [1] - Advanced technology and optimized production processes will significantly enhance the company's production capabilities [1] Group 2: Production Capacity - Upon reaching full production capacity, the project is expected to achieve an annual output of 3,261 tons of raw material formulations and 20 million tablets [1]

Core Viewpoint - Qianjiang Biochemical (600796.SH) announced that its wholly-owned subsidiary, Zhejiang Qichao Biotechnology Co., Ltd. (referred to as "Qichao Biotechnology"), has completed the preliminary construction of the biopesticide raw materials and formulations relocation project, which is now ready for trial operation [1] Group 1 - The project focuses on the research and production of gibberellin series raw materials and formulations, as well as new environmentally friendly pesticide formulations [1] - The implementation of advanced technology and optimization of production processes will significantly enhance the company's production technology level [1] - Upon reaching full production capacity, the project is expected to achieve an annual production capacity of 3,261 tons of raw materials and 20 million tablets [1]

格隆汇10月28日丨钱江生化(600796.SH)发布三季报，2025年前三季度实现营业总收入11.99亿元，同比 下降7.83%；归属母公司股东净利润1.51亿元，同比增长17.49%；基本每股收益为0.17元。 ...

Company Performance - Qianjiang Biochemical reported a revenue of approximately 1.199 billion yuan for the first three quarters of 2025, representing a year-on-year decrease of 7.83% [1] - The net profit attributable to shareholders of the listed company was approximately 151 million yuan, showing a year-on-year increase of 17.49% [1] Market Overview - As of the report, Qianjiang Biochemical has a market capitalization of 5.3 billion yuan [2] - The A-share market has surpassed 4,000 points, indicating a significant market resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [2]

证券代码：600796 证券简称：钱江生化 浙江钱江生物化学股份有限公司 2025 年第三季度报告 浙江钱江生物化学股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 | 量净额 | | | | | | --- | --- | --- | --- | --- | | 基本每股收益（元/股） | 0.05 | 0 | 0.17 | 13.33 | | 稀释每股收益（元/股） | 0.05 | 0 | 0.17 | 13.33 | | 加权平均净资产收益率 （%） | 1.34 | 减少 0.13 个百分点 | 4.53 | 增加 0.5 个百 分点 | | | | | ...

浙江钱江生物化学股份有限公司 Zhejiang Qianjiang Biochemical Co., Ltd 二零二五年第四次临时股东大会会议资料 浙江钱江生物化学股份有限公司 2025 年第四次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会 的顺利进行，根据《公司章程》、公司《股东大会议事规则》等相关法律法规的要求， 特制定本年度股东大会会议须知。 一、董事会以维护股东的合法权益、确保大会正常秩序和议事效率为原则，认真 履行《公司章程》中规定的职责。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务请出席 大会的股东或股东代理人（以下统称"股东"）及相关人员准时到达会场签到确认参 会资格。股东参会登记当天没有通过电话、邮件或传真方式登记的，不在签到表上登 记签到的，或会议正式开始后没有统计在会议公布股权数之内的股东或股东代理人， 不参加表决和发言。 2025 年 10 月 31 日 | | | | 2025年第四次临时股东大会会议须知 2 | | --- | | 2025年第四次临时股东大会会议议程 3 | | 2025年第四次临时股东大会会议议 ...

Core Points - Zhejiang Qianjiang Biochemical Co., Ltd. (referred to as "Qianjiang Biochemical") held its 10th Board of Directors' sixth extraordinary meeting on October 15, 2023, where several important resolutions were passed, including the expansion of business scope, the cancellation of the supervisory board, and amendments to the Articles of Association and its attachments [1]. Group 1 - Qianjiang Biochemical will absorb and merge its wholly-owned subsidiary Haining Jiahui Property Management Co., Ltd., inheriting all assets, liabilities, businesses, and personnel from the subsidiary. The company will expand its business scope to include "property management; non-residential real estate leasing," while other business areas will remain unchanged [2]. - The company plans to amend its Articles of Association and related documents, eliminating the supervisory board and transferring its functions to the audit committee of the board of directors. The positions of supervisors Yu Qiang and Zhu Xiaofang will be terminated, and relevant supervisory rules will be abolished [3]. Group 2 - The rules for shareholder meetings and board meetings have been revised. Changes in the shareholder meeting rules include adjustments to the purpose, powers, conditions for convening, and proposal requirements. The board meeting rules have been modified regarding director nominations, responsibilities, board composition, powers, and meeting procedures [4]. - These measures aim to optimize the corporate governance structure, adapt to business development needs, and enhance operational efficiency and competitiveness. The company will proceed with the necessary business registration procedures after the resolutions are approved at the shareholders' meeting, with the final amendments subject to approval by the business registration management department [4].

二、取消监事会并修订《公司章程》的情况 根据《公司法》《上市公司章程指引》《上市公司股东会规则》《上海证券 交易所股票上市规则》等相关规定，结合公司实际情况，公司拟对《公司章程》 及其附件进行修订。《公司章程》修订后，公司将不再设置监事会，免去余强先 生、朱霞芳女士的监事职务，监事会的职权由董事会审计委员会行使，公司《监 事会议事规则》等监事会相关制度同步废止。具体修订内容如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江钱江生物化学股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日召开的十届董事会 2025 年第六次临时会议，会议审议通过了《关于增加经营 范围、取消监事会并修订《公司章程》的议案》《关于修订<股东会议事规则> 的议案》和《关于修订<董事会议事规则>的议案》。现将有关情况公告如下： 一、增加经营范围的情况 根据公司实际经营发展需要，公司吸收合并全资子公司海宁嘉汇物业管理有 限公司（简称"嘉汇物业"），公司存续经营，嘉汇物业注销，嘉汇物业的全部 资产、负债、业务和人员等依法由公司 ...

证券代码：600796 证券简称：钱江生化 公告编号：2025-048 浙江钱江生物化学股份有限公司 关于召开2025年第四次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第四次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 10 月 31 日 至2025 年 10 月 31 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通 过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户 ...